• LAST PRICE
    2.0300
  • TODAY'S CHANGE (%)
    Trending Down-0.0153 (-0.7481%)
  • Bid / Lots
    1.9100/ 1
  • Ask / Lots
    2.0600/ 3
  • Open / Previous Close
    2.0701 / 2.0453
  • Day Range
    Low 2.0300
    High 2.0800
  • 52 Week Range
    Low 1.5000
    High 12.5100
  • Volume
    3,065
    average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Thursday's close: 2.0453
TimeVolumeRNXT
10:26 ET25002.03
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesRNXT
RenovoRx Inc
18.3M
-1.5x
---
United StatesRMSL
REMSleep Holdings Inc
18.6M
-7.0x
---
United StatesPETV
PetVivo Holdings Inc
19.3M
-3.3x
---
United StatesCTGL
Citrine Global Corp
19.8M
-11.5x
---
United StatesBJDX
Bluejay Diagnostics Inc
15.7M
-2.5x
---
United StatesTNON
Tenon Medical Inc
14.7M
-1.0x
---
As of 2022-10-07

Company Information

RenovoRx, Inc. is a clinical-stage biopharmaceutical company, which is focused on developing therapies for the local treatment of solid tumors and conducting a Phase III pancreatic cancer clinical trial for its lead product candidate RenovoGem. The Company’s therapy platform, RenovoRx Trans-Arterial Micro-Perfusion (RenovoTAMP) utilizes chemotherapeutics. RenovoTAMP combines its patented delivery system, RenovoCath, with small molecule chemotherapeutic agents, which can be forced across the vessel wall using pressure, targeting these anti-cancer drugs locally to the solid tumors. Its first product candidate, RenovoGem, is a drug /device combination consisting of intra-arterial gemcitabine and RenovoCath. RenovoGem has developed for the treatment of two rare diseases: pancreatic cancer and cholangiocarcinoma (CCA). It has completed its Phase I/II and observational registry studies, with 20 and 25 patients respectively, in locally advanced pancreatic cancer (LAPC).

Contact Information

Headquarters
333 W Santa Clara St Ste 900SAN JOSE, CA, United States 95113-1716
Phone
408-800-2649
Fax
302-636-5454

Executives

Chief Executive Officer, Director
Shaun Bagai
Founder, Director, Chief Medical Officer
Ramtin Agah
Founder, consulting technical engineering advisor
Kamran Najmabadi
Chief Financial Officer, Treasurer, Company Secretary
James Ahlers
Chief Operating Officer
Angela Nelms

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$18.3M
Revenue (TTM)
$0.00
Shares Outstanding
9.1M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
---
EPS
$-1.34
Book Value
$1.72
P/E Ratio
-1.5x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.